Aligos Therapeutics Shares Fall 18%

Shares of clinical stage biopharmaceutical company Aligos Therapeutics, Inc. (ALGS) are down 18 percent on Thursday's trading.

The company priced its public offering of 4.4 million shares at $19.00 per share. All the shares are being offered by the company itself. Aligos expects to generate gross proceeds of $83.6 million from the offering, which will close on July 6.

Currently trading at $16.70, the stock has traded between $12.82 and $37.51 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT